Aggressive Colorectal Cancer in an Inflammatory Bowel Disease Patient following Treatment with Vedolizumab: A Case Report

Aggressive Colorectal Cancer in an Inflammatory Bowel Disease Patient following Treatment with Vedolizumab: A Case Report

Introduction: The increased risk of bowel cancer in patients with inflammatory bowel disease can be related with the extent, duration and severity of inflammation or with the cancer immune surveillance interference of immunosuppressive drugs used in inflammatory bowel disease treatment. Therefore, t...

Full description

Bibliographic Details
Main Authors:	Catarina Nascimento, Helena Oliveira, Catarina Fidalgo, Lídia Roque Ramos, Luísa Glória, Joana Torres
Format:	Article
Language:	English
Published:	Karger Publishers 2021-07-01
Series:	GE: Portuguese Journal of Gastroenterology
Subjects:	ulcerative colitis melanoma immunosuppressive therapy vedolizumab azathioprine colorectal cancer
Online Access:	https://www.karger.com/Article/FullText/516673

Similar Items

Vedolizumab in Inflammatory Bowel Disease: West versus East
by: Prasanta Debnath, et al.
Published: (2021-01-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
by: A. O. Golovenko, et al.
Published: (2018-10-01)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
by: Dart RJ, et al.
Published: (2017-03-01)

Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice
by: M. V. Shapina, et al.
Published: (2020-02-01)

Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
by: Petkau JM, et al.
Published: (2016-03-01)

Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab
by: Diana Martins, et al.
Published: (2018-02-01)

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
by: Feuerstein, J.D, et al.
Published: (2022)

Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
by: Jeong Yeon Kim, et al.
Published: (2020-03-01)

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
by: Lieven Pouillon, et al.
Published: (2019-05-01)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
by: Timo Rath, et al.
Published: (2018-07-01)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
by: Benjamin Crooks, et al.
Published: (2020-03-01)

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
by: Manuel Sutter, et al.
Published: (2021-08-01)

Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis
by: Raúl Vicente Olmedo-Martín, et al.

Immunoglobulin A vasculitis in an adult patient receiving vedolizumab therapy for ulcerative colitis: A case report
by: http://www.mdpub.net/index.php?fulltxt=68728&fulltxtj=172&fulltxtp=172-1570485169.pdf
Published: (2019-11-01)

Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
by: Holger Schäffler, et al.
Published: (2017-12-01)

Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK
by: Wilson MR, et al.
Published: (2017-10-01)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
by: Hiroyuki Okamoto, et al.
Published: (2021-01-01)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
by: Friederike Fuchs, et al.
Published: (2017-07-01)

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
by: Choon Jin Ooi, et al.
Published: (2021-01-01)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
by: Ting Zhou, et al.
Published: (2021-08-01)

Human herpesvirus 8-associated colonic Kaposi’s sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature
by: Valerio Papa, et al.
Published: (2020-03-01)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
by: Joseph Meserve, et al.
Published: (2020-04-01)

Fever During Anti-integrin Therapy: New Immunodeficiency
by: Eleonora Bonfanti, et al.
Published: (2020-02-01)

Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
by: Sebastian Zundler, et al.
Published: (2017-07-01)

The Use of Virtual Reality to Reduce Stress among Inflammatory Bowel Disease Patients Treated with Vedolizumab
by: Konrad Lewandowski, et al.
Published: (2021-06-01)

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
by: Hamzah Abu-Sbeih, et al.
Published: (2018-12-01)

Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1
by: Loftus EV Jr, et al.
Published: (2020-06-01)

Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives
by: Gubatan J, et al.
Published: (2021-08-01)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
by: Sophie Restellini, et al.
Published: (2021-03-01)

Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study
by: Stephanie Zwicker, et al.
Published: (2017-08-01)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
by: Matthew Luzentales-Simpson, et al.
Published: (2021-02-01)

Emerging Therapies: What Are Promising in the Near Future?
by: Geom Seog Seo, et al.
Published: (2018-02-01)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
by: Judy A. Trieu, et al.
Published: (2017-12-01)

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
by: Patrizio Scarozza, et al.
Published: (2020-07-01)

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
by: Ulf Helwig, et al.
Published: (2020-07-01)

Alopecia Universalis Associated with Ulcerative Colitis and The Role of Azathioprine
by: Kyrillus S Shohdy, et al.
Published: (2018-01-01)

Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?
by: Raphael P. Luber, et al.
Published: (2019-11-01)

Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
by: Gian Paolo Caviglia, et al.
Published: (2020-03-01)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
by: Lorenzo Bertani, et al.
Published: (2020-05-01)